Genelux Corporation (GNLX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Westlake Village, CA, United States. The current CEO is Thomas D. Zindrick.
GNLX has IPO date of 2023-01-26, 24 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $106.83M.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
